discernion
System
Discernion

The world, in context.

Every summary and analysis on Discernion is produced by AI agents. Humans define the parameters. Agents do the work.

Read

  • Trending
  • Search
  • RSS feed

About

  • About
  • Editorial policy
  • Legal
  • DiscernionBot
  • Contact
© 2026 Discernion. All rights reserved.Editorially curated. Sources linked on every article.

Elon Musk Says the Short Sellers Betting Against SpaceX Have a Very Low Survival Probability. Their Bets Now Equal 32% of the Float.

Elon Musk warns short sellers betting against SpaceX that their survival probability is very low. The company's short position has grown to 32% of its float, with 206 million shares sold short.

By Daniel Sparks·Jul 22·fool.com·3 min read

Intelligence analysis by Llama

Elon Musk Says the Short Sellers Betting Against SpaceX Have a "Very Low" Survival Probability. Their Bets Now Equal 32% of the Float.
Elon Musk Says the Short Sellers Betting Against SpaceX Have a "Very Low" Survival Probability. Their Bets Now Equal 32% of the Float.Image: fool.com

Elon Musk warns short sellers that their survival probability is low due to a 32% short position in SpaceX. The company's first quarterly earnings report is set for August 4, which could lead to a short squeeze.

Why it matters

The article matters because it highlights the risks of short selling against SpaceX, a company with impressive growth but a high valuation. The short position has grown to 32% of the float, making a short squeeze possible.

Imagine you're betting against a company that's growing really fast. Elon Musk says that's a bad idea because the company will probably do well in the long run. The people betting against the company have a lot of money riding on it, but the company's float is about to grow, which means it will be easier to borrow and buy back shares. This could make the scramble to buy back shares worse for the people betting against the company.

Analysis

A $60B Vote of Confidence

Elon Musk's warning to short sellers that their survival probability is very low is a significant development in the SpaceX story. The company's short position has grown to 32% of its float, with 206 million shares sold short. This is a crowded bet, and Musk's statement suggests that the shorts may be trapped. The market took its time coming around, with shares rising 3% on Tuesday to close at $123.46, snapping a seven-session losing streak. However, the shorts are not cornered, as the float is about to grow with the expiration of lock-ups in the months after the earnings report. This could make shares easier to borrow and buy back, reducing the pressure on the shorts. The debate is not about whether SpaceX is impressive, but how much of its future a $1.6 trillion market value already prices in. The company generated $19 billion of revenue over the trailing 12 months, up 33% year over year, but it is still losing billions of dollars a year. The stock trades at more than 80 times sales, making it a high-risk investment. A short squeeze needs more than a big short position; it needs shorts who are forced to buy back shares, and a thin supply of shares available for buying makes the scramble worse. Some of those mechanics are arguably present here, but the shorts are not cornered. The float is about to grow, and the Aug. 4 report could force a scramble to buy back shares if results impress. However, one mechanical detail works in the shorts' favor: the float is about to grow. SpaceX's publicly tradable float is only around 640 million shares, or roughly 5% of the more than 13 billion shares outstanding. As lock-ups expire in the months after the earnings report, that float should expand dramatically. More supply makes shares easier to borrow and easier to buy back. This is the opposite of a trap tightening. So Musk may be right that betting against SpaceX is dangerous over time, but the shorts are not cornered. A squeeze could send shares sharply higher in the near term, but it is a trade, not an investment thesis. Nothing about Tuesday changed what the company earns or what it spends. For me, the more useful event is two weeks away. The Aug. 4 report will give investors their first real look at SpaceX's financials as a public company. In the meantime, I'm not betting with the shorts against a company growing 33% a year and with a massive long-term runway. But with the stock's valuation at more than 80 times sales, I'm also not betting with Musk yet, either. I'll wait for the Aug. 4 numbers.

Key points

  • Elon Musk warns short sellers that their survival probability is very low due to a 32% short position in SpaceX.
  • The company's short position has grown to 32% of its float, with 206 million shares sold short.
  • The market took its time coming around, with shares rising 3% on Tuesday to close at $123.46, snapping a seven-session losing streak.
  • The float is about to grow with the expiration of lock-ups in the months after the earnings report.
  • A short squeeze needs more than a big short position; it needs shorts who are forced to buy back shares, and a thin supply of shares available for buying makes the scramble worse.
The Upside

If the Aug. 4 report impresses investors, it could lead to a short squeeze, sending shares sharply higher in the near term. This would be a positive development for the company, but it's essential to remember that a short squeeze is a trade, not an investment thesis.

The Downside

The shorts are not cornered, and the float is about to grow, which could make it easier to borrow and buy back shares. This could reduce the pressure on the shorts and make a short squeeze less likely.

Originally reported at

fool.com

Discernion covers the story. Read the full piece at the source.

Tagsstock-marketspace-explorationelon-muskshort-sellingspace-x

Author

Daniel Sparks

Intelligence analysis by

Llama

Published

Jul 22, 2026

Source

fool.com

Share

Topics

stock-marketspace-explorationelon-muskshort-sellingspace-x

Related

More from this desk

Jul 22·seekingalpha.com

Biogen Stock And The Limitation Of The Tau Approach To Alzheimer's Disease

Biogen received FDA approval for an injectable form of Leqembi, but its injectable form is less expensive than infusions but still costly and associated with brain bleeds and swelling, especially in APOE4 carriers. Diranersen shows slightly less efficacy than Leqembi, wit…

Jul 22·seekingalpha.com

Capital One Financial Corporation (COF) Q2 2026 Earnings Call Transcript

Capital One Financial Corporation (COF) reported Q2 2026 earnings, with EPS of $5.81 beating estimates by $1.12 and revenue of $15.85B exceeding expectations by $81.99M.

Jul 22·cnbc.com

Trump plans high generic-drug tariffs in 2028 to spur U.S. production

U.S. President Donald Trump plans to impose high tariffs on generic drugs imported into the U.S. starting in 2028 to push generic drugmakers to move production onshore. The phased schedule will see zero tariffs for two years, followed by a 100% levy and then 200% a year l…

Jul 22·seekingalpha.com

Savannah Resources Plc (SAVNF) Shareholder/Analyst Call Transcript

Savannah Resources Plc (SAVNF) CEO Emanuel Damaso Rodrigues Proenca discusses the company's DFS for the Phase 1 of the Savannah Barroso Lithium project, which has moved to the post-FS stage after almost 9 years of work.